The Smith and Nephew Hip Implant Metal Ion Class Action centers on defective metal-on-metal hip replacement devices, particularly the Birmingham Hip Resurfacing (BHR) System, which released dangerous cobalt and chromium ions into patients’ bodies. Over 650 lawsuits have been filed against Smith & Nephew since litigation began, with more than 500 consolidated into a multidistrict litigation (MDL No. 2775) in federal court in Maryland. Patients who received these implants between 2006 and the 2015 recall often experienced severe complications including metallosis (metal poisoning), bone and tissue deterioration, chronic pain, and the need for emergency revision surgeries to remove the failed device. This litigation is one of the largest medical device product liability cases in the United States.
The core issue is that the metal-on-metal design of the BHR System and related products caused accelerated wear, releasing abnormally high concentrations of cobalt and chromium ions into the bloodstream and surrounding tissues. One documented case revealed cobalt levels of 587.9 micrograms per liter—far exceeding safe ranges—and chromium levels of 20.4 micrograms per liter, both of which caused severe local and systemic reactions. Most settlements in this litigation remain confidential, but victims have pursued compensation through group settlements and individual claims for medical expenses, pain and suffering, and lost wages related to revision surgeries. As of 2024, approximately 300 claims against the BHR system remain pending worldwide, though the federal MDL was administratively closed in October 2024 by Judge Catherine C. Blake, preventing new cases from entering the consolidated litigation. Understanding the facts of this case is critical for anyone who received a Smith & Nephew hip implant or for family members of patients who suffered complications.
Table of Contents
- What Products Were Recalled and Why?
- Understanding Metal Ion Contamination and Its Medical Effects
- The Legal Consolidation and MDL Structure
- Settlement Patterns and Compensation Awards
- Medical Evidence and the Metal Ion Threshold Controversy
- Current Case Status and Pending Claims
- What to Do If You Have a Smith & Nephew BHR Hip Implant
- The Broader Context of Metal-on-Metal Hip Implant Litigation
- Conclusion
- Frequently Asked Questions
What Products Were Recalled and Why?
Smith & Nephew’s Birmingham hip Resurfacing (BHR) System was widely implanted from 2006 until a formal recall was issued in June 2015. The BHR is a hip resurfacing device that functions differently from traditional hip replacement surgery—instead of replacing the entire hip joint, the surgeon caps the damaged femoral head and replaces the acetabulum (socket). The BHR System was accompanied by other problem devices including the R3 Acetabular System and the Birmingham Hip Modular Head. Between 2012 and 2016, Smith & Nephew issued multiple recalls for these devices due to high failure rates, reported patient complications, pain, and metallosis. The fundamental design flaw centers on the metal-on-metal bearing surface. When two metal surfaces (cobalt-chromium alloy) rub together inside the body, microscopic metal particles and ions are released over time.
In the case of the BHR, this wear accelerated beyond what manufacturers and surgeons anticipated, leading to excessive metal ion shedding. Unlike traditional metal-on-plastic or ceramic implants that shed far fewer ions, the BHR’s design meant that patients essentially had a source of heavy metal contamination embedded in their hip joint for years. A comparison helps illustrate the scope: normal healthy individuals typically have chromium levels in blood of 0.5 to 2.5 micrograms per liter, while successful, functioning hip implants should produce minimal additional cobalt and chromium. Patients with failing BHR systems, by contrast, experienced levels many times higher. In one medical case, a patient’s cobalt concentration reached 587.9 micrograms per liter—nearly 250 times the upper limit of the normal range. These elevated levels directly triggered the conditions patients sued over: systemic cobalt poisoning, local metallosis at the implant site, and tissue destruction requiring urgent surgical intervention.
Understanding Metal Ion Contamination and Its Medical Effects
Metal ions released from failing hip implants trigger a cascade of harmful reactions in the body. When cobalt and chromium ions migrate into the bloodstream and surrounding tissues, they cause local inflammation, tissue necrosis (death of bone and soft tissue), and can lead to a condition called metallosis—a severe inflammatory response to metal particulates and dissolved ions. Patients describe metallosis as analogous to a chemical burn inside the body; the inflammation spreads, destroying healthy bone and muscle around the implant, weakening the hip joint and making revision surgery increasingly urgent and complex. The medical evidence documenting this damage is substantial. Laboratory investigations in cases of failed BHR implants revealed extreme blood cobalt levels of 587.9 micrograms per liter and chromium levels of 20.4 micrograms per liter. Even in less severe cases, patients showed chromium concentrations well above the normal range of 0.8 to 5.1 micrograms per liter in serum.
The FDA, recognizing the problem, established a nominal safety threshold of 7.0 parts per billion (micrograms per liter) for metal ions, but the agency later acknowledged that even this threshold “is not optimal to determine if an implant is functioning safely.” This is a significant limitation: no universally accepted safe threshold exists, meaning even “regulated” levels can be harmful to individual patients, and the FDA’s own standard proved insufficient to prevent injuries from the BHR. The systemic effects extend beyond the hip joint. Cobalt and chromium ions circulate through the bloodstream, potentially accumulating in organs and tissues far from the implant site. Patients have reported neurological symptoms, cardiac arrhythmias, and autoimmune-like reactions. The revision surgery to remove a failed BHR implant is far more complicated than the original surgery because the implant site is often surrounded by dead or severely damaged bone, requiring reconstruction and specialized techniques. Some patients have required multiple revision surgeries, compounding their physical trauma and medical costs.
The Legal Consolidation and MDL Structure
In April 2017, the Judicial Panel on Multidistrict Litigation consolidated over 500 BHR-related lawsuits into MDL No. 2775, assigned to the U.S. District Court for the District of Maryland under Judge Catherine C. Blake. This consolidation was necessary because the sheer volume of similar claims—all alleging failure of the same defective product—would overwhelm individual district courts and create conflicting rulings across the country.
The MDL mechanism allows one judge to oversee pretrial discovery, motion practice, and settlement negotiations, while preserving each plaintiff’s right to either settle or proceed to trial individually. By the time the MDL was administratively closed in October 2024, the litigation had evolved substantially. Judge Blake issued an order halting new case transfers into the MDL, signaling that the active litigation phase was winding down. However, this does not mean the litigation is resolved; approximately 300 claims against the BHR system remain pending worldwide as of the 2024 Annual Report. The consolidation process took years because BHR implants were used across the globe—the United States, Europe, Canada, and Australia—and coordinating international discovery and legal standards created logistical complexity. Notably, a potential class action certification effort in Canada was discontinued as of April 18, 2024, reducing the scope of coordinated litigation but leaving individual Canadian patients to pursue claims separately or through alternative mechanisms.
Settlement Patterns and Compensation Awards
Unlike some high-profile product liability cases that reach jury verdicts reported in the news, most settlements in the Smith & Nephew BHR litigation have been structured as confidential group settlements and individual agreements. This means the public rarely learns specific dollar amounts awarded to victims. Drugwatch and legal tracking organizations have documented that cases were dismissed after settlement in August 2023 and November 2024, but the agreed-upon amounts remained confidential under standard settlement agreements. The confidential nature of these settlements creates both advantages and disadvantages for future claimants. On one hand, settlement confidentiality allowed Smith & Nephew to avoid the reputational damage of published jury verdicts that might have been in the millions per plaintiff.
On the other hand, victims lack transparency about what compensation their peers received, making it difficult to evaluate whether a settlement offer is fair. A plaintiff with severe metallosis requiring multiple revision surgeries might receive compensation ranging from hundreds of thousands to potentially millions of dollars for medical costs, lost wages, pain and suffering, and permanent disability, but without published verdicts as benchmarks, negotiating a fair settlement becomes challenging. This is a crucial limitation of the confidential settlement structure: it protects the defendant’s reputation while disadvantaging future claimants who have no market data to evaluate offers. Many settlements in medical device litigation account for factors including the severity of injury, the number and cost of revision surgeries, documented metal ion levels, and the length of implant failure. Plaintiffs with higher cobalt and chromium readings, more extensive tissue damage, and greater medical expenses typically negotiate larger awards. However, the confidentiality of individual cases means this information rarely becomes public, leaving later claimants to work with legal counsel to estimate value based on general knowledge of the market.
Medical Evidence and the Metal Ion Threshold Controversy
The scientific evidence documenting the dangers of the BHR system comes from published medical research, FDA communications, and case-specific laboratory testing. Studies have documented average chromium concentrations ranging from 0.5 to 2.5 micrograms per liter in blood and 0.8 to 5.1 micrograms per liter in serum among patients with normal, functioning implants. In contrast, failing BHR devices produced dramatically higher readings. The extreme example of 587.9 micrograms per liter cobalt—mentioned in published research on metal-on-metal hip joint prostheses—represents a 20-fold or greater elevation compared to what might be expected even from a moderately symptomatic failed implant. A critical issue in this litigation is the absence of a universally agreed-upon “safe” metal ion threshold. The FDA established a nominal 7.0 parts per billion (micrograms per liter) threshold, but the agency itself concluded that this level “is not optimal to determine if an implant is functioning safely.” This regulatory uncertainty created a gap in medical guidance: surgeons and patients lacked a clear standard for when to act.
A patient whose cobalt level tested at 5.0 micrograms per liter might be told the level is “below the FDA threshold” and therefore acceptable, yet still experience progressive metallosis and organ toxicity. This warning is particularly important for patients considering whether to pursue revision surgery on their own initiative versus waiting for symptoms to worsen; the regulatory framework did not provide adequate guidance, leaving decisions to individual physicians and patient tolerance. The metallosis process itself is documented in medical literature but occurs variably among patients. Some individuals showed aggressive inflammatory responses and rapid bone destruction; others had slower-progressing damage. This individual variation means that metal ion levels alone do not fully predict the severity of a patient’s condition. A patient with the same cobalt reading as another might experience minimal symptoms initially but develop severe complications years later. For this reason, medical experts in the litigation had to evaluate each case based on the patient’s specific clinical presentation, imaging studies, and laboratory values rather than relying on a single biomarker.
Current Case Status and Pending Claims
As of 2024, the landscape of Smith & Nephew BHR litigation has shifted significantly. The federal MDL in Maryland, which had served as the coordinating mechanism for hundreds of cases, entered an administrative closure phase in October 2024 under Judge Blake’s order. Administrative closure does not mean the cases are resolved; rather, it means the MDL is no longer accepting new transfers and is handling only remaining administrative matters.
This change reflects the maturity of the litigation—most active discovery is complete, and the bulk of settlements have been negotiated. However, approximately 300 claims against the BHR system remain pending worldwide. These pending cases involve plaintiffs who either did not settle during the MDL’s active period, are pursuing claims in state court or international jurisdictions, or are newly identified victims whose BHR implants have recently failed. The closure of the MDL also means that any new BHR cases filed after October 2024 will not be automatically consolidated; instead, they will proceed as individual lawsuits in their respective courts, which could result in inconsistent outcomes and may disadvantage future plaintiffs who lack the collective leverage and shared discovery that the MDL provided.
What to Do If You Have a Smith & Nephew BHR Hip Implant
If you received a Birmingham Hip Resurfacing device or related Smith & Nephew hip implant between 2006 and 2016, the first step is to confirm the specific product implanted by reviewing your surgical records or contacting your surgeon’s office. Your operative report should clearly identify the device model and serial number. Next, discuss with your physician whether you have experienced any symptoms associated with metallosis, including chronic pain not relieved by physical therapy, swelling or stiffness that worsens over time, or clicking or grinding sensations in the hip joint. If you have symptoms, request blood tests measuring cobalt and chromium levels. While the FDA’s 7.0 parts per billion threshold is imperfect, abnormally elevated readings provide objective evidence of metal ion release.
Imaging studies such as X-rays, MRI, or CT scans can reveal signs of bone loss or tissue damage around the implant. If testing suggests implant failure, consult with a hip surgeon about revision surgery options and timeline. Meanwhile, if you experienced complications from an BHR implant, contact an attorney experienced in product liability or medical device litigation. Many law firms handling Smith & Nephew BHR cases work on a contingency basis, meaning you pay nothing upfront and the attorney is paid only if a settlement or judgment is obtained. An attorney can evaluate your case, estimate potential compensation based on the severity of your injuries and medical expenses, and initiate settlement negotiations or litigation if appropriate.
The Broader Context of Metal-on-Metal Hip Implant Litigation
The Smith & Nephew BHR litigation is one of multiple metal-on-metal hip implant controversies that emerged in the 2010s. Other defendants, including DePuy (the Pinnacle hip system) and Zimmer, faced similar lawsuits alleging elevated metal ion shedding and patient harm. The collective impact of these litigations prompted the FDA and international regulatory bodies to increase scrutiny of metal-on-metal bearing surfaces and to require manufacturers to provide more robust follow-up data on implant longevity and metal ion profiles. For Smith & Nephew specifically, the BHR litigation—involving over 650 lawsuits and 500 consolidated cases—represents one of the company’s most significant product liability exposures and has influenced how the company designs, tests, and markets hip implants going forward.
The conclusion of active MDL litigation in 2024 does not signal resolution of the underlying public health issue. Patients worldwide still have failing BHR implants in their bodies, and revision surgeries continue. The scientific understanding of metal ion toxicity has advanced significantly since the BHR was first implanted, but patients who received these devices in the 2006-2015 window were essentially unknowing participants in a large-scale medical experiment. The confidential settlement structure means that future patients will not benefit from transparent knowledge of how much their predecessors were compensated, making it essential for new victims to seek legal counsel promptly to protect their interests.
Conclusion
The Smith and Nephew Hip Implant Metal Ion Class Action represents a significant product liability litigation involving defective metal-on-metal hip resurfacing devices that released dangerous cobalt and chromium ions into patients’ bodies, causing metallosis, bone destruction, and the need for complex revision surgeries. Over 650 lawsuits have been filed against Smith & Nephew, with more than 500 consolidated into MDL No. 2775 in federal court in Maryland.
Approximately 300 claims remain pending, though the MDL entered administrative closure in October 2024, signaling the end of the active litigation phase but not the resolution of patients’ claims. If you received a Smith & Nephew BHR hip implant or related device and have experienced complications, document your symptoms, obtain blood tests measuring metal ion levels, and consult with an experienced product liability attorney. Most BHR settlement cases have been resolved confidentially, but future claimants still have the right to pursue compensation for medical expenses, pain and suffering, and disability. Act promptly, as litigation deadlines may apply, and attorneys can evaluate your case at no upfront cost.
Frequently Asked Questions
What is the Birmingham Hip Resurfacing (BHR) System?
The BHR is a hip resurfacing implant that caps the damaged femoral head and replaces the hip socket, rather than replacing the entire hip joint as in traditional hip replacement. Smith & Nephew’s BHR System used a metal-on-metal bearing surface and was widely implanted from 2006 until a recall in June 2015.
Why did the BHR System fail and cause metal ion poisoning?
The metal-on-metal design of the BHR System caused excessive wear over time, releasing cobalt and chromium ions into the bloodstream and surrounding tissues. This metal ion shedding triggered inflammation, metallosis, bone death, and tissue destruction, requiring revision surgeries.
What is metallosis and how does it develop?
Metallosis is an inflammatory reaction to metal particles and ions released from failed implants. Cobalt and chromium ions migrate from the failing hip implant into the bloodstream and local tissues, causing pain, swelling, bone loss, and tissue necrosis that mimics a chemical burn inside the body.
How many lawsuits were filed against Smith & Nephew for BHR implants?
Over 650 lawsuits have been filed against Smith & Nephew for BHR-related injuries. More than 500 of these cases were consolidated into MDL No. 2775 in U.S. District Court for the District of Maryland under Judge Catherine C. Blake.
Are there any pending BHR cases, or is the litigation finished?
As of 2024, approximately 300 claims against the BHR system remain pending worldwide, even though the federal MDL was administratively closed in October 2024. The closure prevents new cases from entering the MDL, but existing cases continue to be resolved.
How much compensation have BHR victims received?
Most settlements in the BHR litigation are confidential and amounts are not publicly disclosed. Compensation typically accounts for medical expenses, revision surgery costs, pain and suffering, and lost wages, but without published verdicts, exact amounts vary by case and are negotiated individually.